Cannabidiol as potential treatment in refractory pediatric epilepsy

Maria Chiara PaolinoChild Neurology, Headache Paediatric Center, Paediatric Sleep Disorders, NESMOS Department, Chair of Pediatrics, Faculty of Medicine and Psychology, Sapienza University, c/o Sant’Andrea Hospital, Rome, Italy

Alessandro FerrettiChild Neurology, Headache Paediatric Center, Paediatric Sleep Disorders, NESMOS Department, Chair of Pediatrics, Faculty of Medicine and Psychology, Sapienza University, c/o Sant’Andrea Hospital, Rome, Italy

Laura PapettiDepartment of Pediatrics, Child Neurology Division, Sapienza University of Rome, Rome, Italy

Maria Pia VillaChild Neurology, Headache Paediatric Center, Paediatric Sleep Disorders, NESMOS Department, Chair of Pediatrics, Faculty of Medicine and Psychology, Sapienza University, c/o Sant’Andrea Hospital, Rome, Italy

Pasquale ParisiChild Neurology, Headache Paediatric Center, Paediatric Sleep Disorders, NESMOS Department, Chair of Pediatrics, Faculty of Medicine and Psychology, Sapienza University, c/o Sant’Andrea Hospital, Rome, ItalyCorrespondence[email protected] [email protected]

Abstract

In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a favorable side-effect profile. In humans, CBD efficacy and safety is not supported by well-designed trials and its use has been described by anecdotal reports. It will be necessary to investigate CBD safety, pharmacokinetics and interaction with other anti-epileptic drugs (AEDs) alongside performing double-blinded placebo-controlled trials in order to obtain conclusive data on its efficacy and safety in children.

Keywords:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Cannabidiol as potential treatment in refractory pediatric epilepsy

Information for

Open access

Opportunities

Help and information

Cannabidiol as potential treatment in refractory pediatric epilepsy

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature